Search results for " adjuvant chemotherapy"

showing 6 items of 6 documents

Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study

2005

The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer. Patients with histologically proven, radically resected stage II or III colon or rectal cancer were eligible. The study had a 2x2 factorial design with four treatment arms: (a) 5FU alone, (b) 5FU+LEV, (c) 5FU+FA, (d) 5FU+LEV+FA, and two planned comparisons, testing the role of LEV and of FA, respectively. From March 1991, to September 1998, 1327 patients were randomised. None of the two comparisons resulted in a significant disease-free (DFS) or overall (OAS) survival a…

AdultMaleCancer Researchmedicine.medical_specialtyRandomization5-fluorouracil modulation; adjuvant chemotherapy; colorectal cancermedicine.drug_classColorectal cancerLeucovorincolorectal cancerAntimetaboliteGastroenterologyDisease-Free SurvivalFolinic acidRECTAL CANCER5-fluorouracil modulationCOLONInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansAgedbusiness.industryHazard ratioMiddle Agedmedicine.diseaseSurgeryadjuvant chemotherapyTreatment OutcomeLevamisoleOncologyChemotherapy AdjuvantFluorouracilVomitingFemaleFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugBritish Journal of Cancer
researchProduct

TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Ye…

2003

Abstract OBJECTIVES: To evaluate a highly selected population of patients affected by T1G3 bladder transitional cell carcinoma (TCCB) treated by transurethral resection (TUR) and adjuvant intravesical chemotherapy. MATERIALS AND METHODS: Between January 1976 and April 1999, 137 patients with T1G3 TCCB were treated by TUR plus intravesical chemotherapy. Particularly, a sequential combination of mitomycin C (MMC) and epirubicin (EPI) was adopted in 91 patients (66.4%). The main exclusion criteria were concomitant or previous Tis, previous T1G3 TCCB, tumor size greater than 3 centimeters and number of tumors more than 3. TUR was repeated if a superficial tumor recurred. Patients went off study…

Adultmedicine.medical_specialtyTime FactorsUrologyPopulationUrologyIntravesical adjuvant chemotherapyDisease-Free SurvivalSettore MED/24 - UrologiaT1G3 bladder cancermedicineAdjuvant therapyHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryMiddle Agedmedicine.diseaseSurgerySurvival Ratemedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantTumor progressionConcomitantDisease ProgressionUrologic Surgical ProceduresNeoplasm Recurrence LocalbusinessConservative treatmentFollow-Up StudiesEpirubicinmedicine.drugEuropean Urology
researchProduct

Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubi…

2010

International audience; Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse sequence in RPBC. Patients with node-negative or 1-3 node-positive RPBC (Thymidine Labeling Index > 3% or histological grade 3 or S-phase > 10% or Ki67 > 20%) were randomized to receive E (100 mg/m i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m i.v. d1 and 8, q2…

OncologyCancer ResearchSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRandomized phase III study0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsCMFMedicineProspective Studies0303 health sciencesCMF; Epirubicin; Randomized phase III study; Rapidly proliferating breast cancer; Sequential adjuvant chemotherapy strategySequential adjuvant chemotherapy strategy – Epirubicin – CMF – Randomized phase III study – Rapidly proliferating breast cancerSequential adjuvant chemotherapy strategyHazard ratioMiddle Aged3. Good healthTreatment OutcomeReceptors EstrogenOncologyFluorouracilLymphatic Metastasis030220 oncology & carcinogenesisFemaleFluorouracilBreast diseaseRapidly proliferating breast cancermedicine.drugEpirubicinAdultmedicine.medical_specialtyCyclophosphamidebreast cancer epirubicinBreast NeoplasmsNeutropeniaModels Biological03 medical and health sciencesBreast cancerInternal medicineHumansCyclophosphamideAgedProportional Hazards ModelsEpirubicin030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseSurgeryMethotrexatebusinessBreast Cancer Research and Treatment
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

A RANDOMISED STUDY EVALUATING MAINTENANCE SCHEDULE IN EARLY ADJUVANT CHEMOTHERAPY FOR INTERMEDIATE RISK NON-MUSCLE-INVASIVE BLADDER CANCER

2008

ABSTRACT Introduction and Objective: Adjuvant intravesical chemotherapy or BCG immunotherapy after transurethral resection (TUR) is a standard treatment for non–muscle-invasive transitional cell cancer of the bladder (NMI TCCB) at intermediate risk. Although the clinical value of early intravesical adjuvant chemotherapy is well established, the optimal schedule regimen and the role of maintenance is still debated. Methods: Between May 2002 and August 2003, 577 patients, undergoing TUR for NMI TCCB, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology was availa…

Oncologymedicine.medical_specialtyScheduleBladder cancerAdjuvant chemotherapybusiness.industryUrologymedicine.diseasebladder cancer EARLY ADJUVANT CHEMOTHERAPYInternal medicinemedicineNon muscle invasivebusinessIntermediate riskEuropean Urology Supplements
researchProduct

Efficacy of one-year maintenance in early adjuvant chemotherapy for intermediate risk non-muscle-invasive bladder cancer. Preliminary results of a ra…

2008

Introduction and Objective: The clinical value of early intravesical adjuvant chemotherapy after TUR of intermediate risk non-muscle-invasive bladder cancer (NMI TCCB) is well established. On the other hand, the optimal schedule regimen and the role of maintenance are still debated. The aim of the present study was to evaluate the effectiveness of one-year maintenance schedule in patients submitted to TUR plus adjuvant early intravesical chemotherapy. Methods: Between May 2002 and August 2003, 577 patients, were recruited. All patients underwent TUR and early (within 6 hours) intravesical chemotherapy with epirubicin at the dose of 80 mg diluted in 60 ml of saline solution. When histology w…

non-muscle-invasive bladder cancer adjuvant chemotherapy
researchProduct